{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:19:57Z","timestamp":1763774397031,"version":"3.45.0"},"reference-count":16,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) improve cancer survival but can provoke new or worsening autoimmune disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To explore the association of ICIs with multiple sclerosis (MS) using the U.S. Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS) database, and to compare the disproportionality signal of MS with that of other autoimmune neurological adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Secondary analysis of the FAERS database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a disproportionality analysis of FAERS between 2003-Q4 and 2024-Q2. Outcomes were MS, myasthenia gravis (MG), Guillain\u2013Barr\u00e9 syndrome (GBS), and autoimmune encephalitis (AIE). A signal required \u2a7e3 reports, proportional reporting ratio \u2a7e2, and \u03c7\u00b2\u2009\u2a7e\u20094.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 48 reports of MS or MS relapse associated with ICIs. The reporting odds ratio (ROR) for MS or MS relapse was 0.09 (95% confidence interval (CI): 0.068\u20130.12). In comparison, RORs were 21.05 (95% CI: 19.287\u201322.974) for MG, 8.075 (95% CI: 6.677\u20139.766) for GBS, and 29.03 (95% CI: 23.564\u201335.764) for AIE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We found no significant safety signal for MS with ICIs, in contrast to MG, GBS, and AIE. This heterogeneity underscores the need for continued pharmacovigilance and mechanistic research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17562864251392211","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:39:57Z","timestamp":1763455197000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting System"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-6426","authenticated-orcid":false,"given":"Afsaneh","family":"Shirani","sequence":"first","affiliation":[{"name":"Saint Luke\u2019s Marion Bloch Neuroscience Institute, 4401 Wornall Rd, Kansas City, MO 64111, USA Department of Neurology, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel A.","family":"Goldlust","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Marion Bloch Neuroscience Institute, Kansas City, MO, USA"},{"name":"Saint Luke\u2019s Cancer Institute, Kansas City, MO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0469-6872","authenticated-orcid":false,"given":"Olaf","family":"Stuve","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Neurology Section, VA North Texas Health Care System, Dallas, TX, USA"},{"name":"Peter O\u2019Donnell Jr. Brain Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16547"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157753"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200202"},{"key":"e_1_3_4_10_2","article-title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis","volume":"10","author":"Nylander AN","year":"2024","unstructured":"Nylander AN, Rowles W, Poole S, et al. Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis. Mult Scler J Exp Transl Clin 2024; 10: 20552173241252563.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585221117949"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000206683"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2022.06.023"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70173-X"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165248"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309439"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251392211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251392211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251392211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T01:17:21Z","timestamp":1763774241000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251392211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":16,"alternative-id":["10.1177\/17562864251392211"],"URL":"https:\/\/doi.org\/10.1177\/17562864251392211","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"type":"print","value":"1756-2864"},{"type":"electronic","value":"1756-2864"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251392211"}}